随机对照试验的系统综述 尼吉拉·萨蒂瓦 (黑种子) 在代谢综合征中的使用
S Elhariri1, I Burud1, N A Zulaimy2
1Department of Surgery, International Medical University(IMU), Clinical Campus, Seremban, Malaysia. Tel., (+60) 1137778327;
West African journal of medicine
|July 13, 2024
概括
尼日利亚草显著改善了代谢综合征患者的脂质概况和血糖水平. 虽然对血压和体重的影响不那么一致,但作为一种补充疗法,它显示出希望.
科学领域:
- 营养科学 营养科学
- 综合医学是一个整体的医学.
- 公共卫生 公共卫生
背景情况:
- 代谢综合征的特点是肥胖,脂质不良,高血压和葡萄糖不耐受,影响了25-40%的马来西亚成年人.
- 它是心血管疾病的重要危险因素.
- 尼格拉·萨蒂瓦对代谢综合征参数的潜在影响需要进行系统评估.
研究的目的:
- 系统地审查Nigella Sativa对主要代谢综合征指标的影响.
- 评估其对脂质特征,血压,血糖和人体测量测量的影响.
主要方法:
- 2011年1月至2021年12月期间发表的随机对照试验的系统审查.
- 在PubMed和Scopus数据库中进行的搜索.
- 使用Cochrane协作工具进行偏见风险评估.
主要成果:
- 在脂质样本 (6/8试验) 和血糖控制 (5/7试验) 中观察到显著改善.
- 血压 (1/5试验) 和人类测量 (2/7试验) 的不一致效应被注意到.
结论:
- 尼日利亚树在代谢综合征中对脂质概况和血糖控制具有显著的益处.
- 它对血压和人体测量的疗效需要进一步研究.
- 尼日利亚可以作为一种有效的辅助疗法来治疗代谢综合征.
更多相关视频
13:09Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet
Published on: July 31, 2021
3.7K
06:04Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
Published on: September 27, 2024
851
相关概念视频
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
Oral Hypoglycemic Agents: Biguanides and Glitazones
187
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
187
